The $50M insider purchase by ARCH Venture Partners affiliates is a strong vote of confidence in Lyell's prospects, particularly given the timing with the Q3 earnings release and positive ronde-cel data. The executive sales are de minimis and likely personal liquidity. Monitor for any additional insider buying or updates on the BLA submission timeline for ronde-cel in H2 2027.
Drug in focus
LYEL drug pipeline →ronde-cel
▲ Bullish Named in this insider cluster- Impact
- Phase
- Phase 3
- Time to market
- Pivotal data from the PiNACLE trial is expected mid-2027, with a BLA submission planned for the second half of 2027. If approved, commercial launch would likely follow in 2028.
- Next catalyst
- None dated
What to watchThe next major catalyst is the ASH 2026 Annual Meeting (December 12-15, 2026), where updated data from the PiNACLE pivotal trial (3L+) and the Phase 1/2 second-line cohort will be presented in oral and poster sessions. Strong data could drive the stock toward analyst targets (mean $37.88), while disappointing durability or safety signals would pressure shares. The pivotal data readout expected in mid-2027 and BLA submission in H2 2027 are the longer-term binary events.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $14.30entry
- T+1 · 20h ago +2.45%α +4.36% · $14.65
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two 10% owner affiliates of ARCH Venture Partners purchased $50M in open-market shares on November 4, 2026, while three executives sold a combined $19K in open-market sales on November 10, 2026. The insider buying follows Lyell's Q3 2026 earnings release on November 4, which highlighted strong ronde-cel clinical data and an $80M private placement extending cash runway into 2028.
Key Financial Metrics
Key Facts
- ARCH Venture Partners IX and ARCH Venture Fund XIII each purchased 2.32M shares at $10.77, totaling $50M in open-market buys on November 4, 2026.
- Three executives sold a combined $18,765 in open-market sales on November 10, 2026, at $15.93 per share.
- The insider buying occurred on the same day as Lyell's Q3 2026 earnings release, which reported a GAAP net loss of $45.5M but highlighted strong ronde-cel clinical data and an $80M private placement.
- The $50M insider purchase represents approximately 12.1% of Lyell's $412M market cap, a highly material signal.
- The executive sales are trivial in size (0.005% of market cap) and likely unrelated to the ARCH purchases.
Financial Impact
Two 10% owner affiliates purchased $50M in open-market shares, representing 12.1% of market cap. Executive sales were $19K, immaterial.
Risk Factors
- The company reported a widening GAAP net loss of $45.5M in Q3 2026, though the $80M private placement extends cash runway into 2028.
- The stock price has risen from $10.77 (the ARCH purchase price) to $15.93 (the executive sale price) in six trading days, suggesting potential short-term volatility.
- Ronde-cel BLA submission is not expected until H2 2027, leaving a long period without a near-term catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-LYEL-1794518040143 |
Track record
21 reports on LYEL
4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Bullish 6/10 Viewing Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
- Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
- Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
- Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers